Medicare Policy Changes for Women’s Healthcare in 2026

The Australian government’s 2026 Medicare policy changes, centered on a $792 million Women’s Health Package, provide immediate cost relief and expanded services for women. Effective January 1, 2026, the PBS maximum co-payment drops to $25 per prescription, saving approximately $6.60 per script. Additional reforms include free BreastScreen mammograms for women aged 50-74, 3D breast tomosynthesis coverage from March 2026, and rebates for menopause assessments.

The package also funds 33 specialist endometriosis clinics and new PBS listings for critical cancer medicines. These updates honor the legacy of the late Peta Murphy MP and address long-standing barriers in women’s healthcare across Australia, including for those seeking women’s health services.

How Do 2026 Medicare Policy Changes Affect Women’s Healthcare?

Policy Announcement, Timeline, and Legacy

The $792 million Women’s Health Package was announced in the 2025 federal budget by the Albanese government, marking a historic investment in gender-specific healthcare. The package responds to longstanding gaps in women’s health services, from affordable prescription medicines to specialized care for conditions like endometriosis and menopause. Key reforms took effect on January 1, 2026, including the reduction of the PBS maximum co-payment to $25 per script.

Additional Medicare Benefits Schedule (MBS) updates, such as coverage for 3D breast tomosynthesis, became operational in March 2026. These changes honor the legacy of the late Peta Murphy MP, a dedicated advocate for cancer patients and women’s health whose parliamentary work highlighted the need for better access to screenings and treatments. The swift implementation—within a year of the budget announcement—demonstrates a strong commitment to delivering tangible improvements for Australian women.

By simultaneously lowering drug costs and expanding service coverage, the package tackles both financial and access barriers, setting a new standard for women’s healthcare in Australia. The $792 million package is part of broader health policy reforms for gender-specific care announced in the 2025 budget.

These reforms reflect the growing women’s rights and health equity advocacy across Australia. The investment is expected to benefit millions of women nationwide, particularly those with chronic conditions or lower incomes who often face higher out-of-pocket expenses.

Key Components of the $792M Women’s Health Package

Policy Change	Effective Date	Key Statistics/Details
PBS maximum co-payment reduction	January 1, 2026	Reduced from $31.60 to $25 per script for general patients; concession holders pay $7.70 (health.gov.au, Feb 9, 2026)
Free BreastScreen mammograms	Ongoing	Women aged 50-74 receive free mammograms every two years (health.gov.au)
3D breast tomosynthesis coverage	March 2026	Added to MBS for breast cancer imaging, providing more accurate detection than 2D mammography (mbsonline.gov.au)
Self-collected cervical screening	2026	New option introduced, improving access for women who may face barriers to traditional screening (health.gov.au)
Menopause assessment rebates	Available since July 2025	71,000+ assessments claimed by February 2026; $49 million invested (health.gov.au, Feb 2026)
Specialist endometriosis clinics	Operational in 2026	33 clinics established across Australia to provide multidisciplinary care (alp.org.au)
New PBS listings for cancer medicines	Various dates in 2026	Olaparib (Lynparza) for BRCA+ breast cancer; Verzenio for high-risk early breast cancer; Keytruda for urothelial cancer; Lenvima for liver cancer (health.gov.au snippets)

The $792 million package represents a comprehensive strategy that touches nearly every aspect of women’s health. It combines immediate cost savings—like the PBS co-payment cut—with long-term infrastructure investments such as 33 new endometriosis clinics. The inclusion of 3D tomosynthesis and self-collected cervical screening modernizes preventive care, while the $49 million for menopause assessments addresses a frequently overlooked life stage.

New PBS listings for cancer medicines, including olaparib and Verzenio, ensure that cutting-edge treatments are affordable for breast cancer patients. Together, these components create a safety net that reduces financial strain, improves early detection, and expands access to specialist care.

The package’s breadth reflects an understanding that women’s health needs are diverse and interconnected, requiring coordinated solutions across the healthcare system. Additionally, the package has already generated $73 million in savings on contraceptives, menopause, and fertility treatments, further easing cost pressures.

PBS Co-payment Reduction: Lowering Drug Costs for Women

The $25 Maximum Co-payment: Detailed Savings Analysis

Patient Type	Previous Co-payment	New Co-payment (Jan 2026)	Savings per Script
General patient	$31.60	$25.00	$6.60
Concession holder	(previous rate not specified in reforms)	$7.70	(not applicable)
Potential annual savings (12 scripts)	–	–	$79.20 for general patients

For women managing chronic conditions—such as diabetes, autoimmune disorders, or mental health issues—prescription costs can accumulate rapidly. The $6.60 saving per script may appear small, but over a year it can amount to hundreds of dollars. A woman taking 12 different medications saves $79.20 annually; those on 20 scripts save $132.

These savings are especially critical for low-income households and single mothers, who often prioritize children’s needs over their own health. The reduction also benefits women with cancer. Many life-prolonging cancer drugs, now PBS-listed, previously cost tens of thousands of dollars per year.

With the $25 cap, patients pay only a fraction, making treatment financially sustainable. While concession holders already pay a reduced fee of $7.70, the previous rate is not specified in the reforms; nonetheless, the new structure ensures that no patient pays more than $25 per script, providing a clear ceiling for out-of-pocket drug expenses. A detailed health policy analysis of 2026 reforms shows how these changes reduce out-of-pocket costs for women.

Bulk Billing, Medicare Safety Net, and MBS Updates

The PBS co-payment reduction is amplified by complementary Medicare changes. Increased bulk billing incentives encourage doctors to bulk bill patients, meaning women incur no cost at the time of a GP visit. This is vital because women, particularly those with chronic illnesses, consult doctors more frequently than men.

The Medicare Safety Net thresholds have been adjusted upward for 2026, so families with high medical expenses receive greater rebates once they exceed the threshold, effectively capping annual out-of-pocket costs. In March 2026, the MBS added new items for women’s health services, including item 55080 for specific ultrasounds and item 11714 for ECG tests. These updates ensure that essential diagnostic procedures are covered without additional charges.

Collectively, these measures—lower drug costs, free consultations, and expanded procedure coverage—create a robust safety net. For a woman with endometriosis, this could mean free GP appointments, subsidized pain medication, and covered ultrasounds, all reducing financial stress and enabling consistent treatment adherence. For a comprehensive overview of Medicare changes, see the women’s health policy updates.

Expanded Women’s Health Services: Breast Cancer, Menopause, and Endometriosis

Breast Cancer Screening: Free Mammograms and 3D Tomosynthesis

BreastScreen Australia offers free mammograms every two years to women aged 50-74, eliminating cost as a barrier to early detection. Early-stage breast cancer has a 5-year survival rate exceeding 90%, but this drops sharply if diagnosed late. Starting March 2026, 3D tomosynthesis will be covered under the MBS for breast cancer imaging.

This technology captures multiple X-ray images from different angles to construct a 3D view of the breast, improving cancer detection rates—especially in women with dense breast tissue—and reducing false positives that lead to unnecessary recalls. The addition of 3D tomosynthesis means women can access this superior screening at no extra cost. The package also expands cervical screening by permitting self-collected samples, a less invasive option that may increase participation among women who avoid traditional Pap smears due to discomfort or cultural reasons.

With breast cancer recurrence risk at 1-in-3, regular screening is essential. These reforms remove financial hurdles and harness advanced technology to catch cancers earlier, ultimately saving lives. These reforms build on ongoing advocacy, including breast cancer advocacy progress, and align with 2026 breast cancer screening guidelines that recommend advanced imaging.

Menopause and Endometriosis Care: Uptake and Investment

• Menopause assessments: Since rebates became available in July 2025, over 71,000 assessments have been claimed by February 2026, representing a $49 million government investment (health.gov.au, Feb 2026). This makes specialist menopause care more affordable.
• Endometriosis clinics: 33 specialist clinics are now operational across Australia, providing multidisciplinary treatment for a condition that affects an estimated 1 in 9 women. These clinics are a key component of the $792 million Women’s Health Package (alp.org.au).
• Overall savings: The package has generated $73 million in savings on contraceptives, menopause treatments, and fertility services, further reducing financial burdens (alp.org.au).

The rapid uptake of menopause assessments—over 71,000 in just seven months—reveals a massive unmet need.

Many women suffer for years with symptoms like hot flashes, sleep disturbances, and mood swings without proper diagnosis or treatment. These rebates enable access to endocrinologists and gynaecologists who can prescribe hormone therapy or other interventions. The 33 endometriosis clinics aim to slash diagnosis delays, which currently average 7-10 years from symptom onset.

By offering coordinated care—including surgery, pain management, and fertility support—these clinics improve quality of life and reduce the need for repeated hospitalizations. The investment in endometriosis clinics complements cancer awareness initiatives in 2026 that focus on early detection and education. Together, these investments signal a shift toward treating women’s health conditions with the seriousness and resources they deserve, moving beyond stigma and neglect.

The most surprising finding is the explosive demand for menopause care—71,000+ assessments in just seven months—highlighting how many women have struggled without support. This underscores the importance of the 2026 Medicare reforms. Women should immediately review their Medicare eligibility and discuss with their GP the new rebates for breast cancer screenings, menopause management, and endometriosis treatment.

For the latest updates, visit the Department of Health and Aged Care website. These changes represent a significant step toward equitable, affordable healthcare for all Australian women. Staying informed ensures you can take full advantage of these benefits as they become available.